EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adjuvant FLOT provides survival benefit for oesophagogastric junction and gastric adenocarcinoma patients with low tumour regression after neoadjuvant chemotherapy

Max Kraemer iD, Naita M Wirsik, Hakan Alakus, Hans A Schloesser, Hans Fuchs, Wolfgang Schroeder, Christiane J Bruns, Su Ir Lyu, Friederike Baehr, Thomas Zander, Alexander Quaas

International Journal of Cancer · 2025

DOI: 10.1002/ijc.70048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Max Kraemer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Gastrointestinal Cancer Group Cologne GCGC, Univer…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Esophagogastric Junction, Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oesophagogastric junction and gastric adenocarcinoma (OGA) are associated with high mortality rates, with 5‐year survival rates below 50% in the curative setting. This study evaluates the efficacy of adjuvant chemotherapy (a chemotherapy regimen consisting of docetaxel, oxaliplatin, leucovorin and 5‐fluorouracil [FLOT]) in patients with low tumour regression grades (TRG) following neoadjuvant FLOT (>10% viable tumour cells in surgical specimen, TRG 2/3 analogue Becker's classification). Data from all patients who had undergone ≥3 cycles of neoadjuvant FLOT with R0 resection and TRG 2/3 in surgical specimen, diagnosed between 2017 and 2020 at the University of Cologne ( n = 134), were analyzed. Patients were categorised into three groups based on the administration of postoperative FLOT: ‘FLOT complete’ (four cycles), ‘FLOT incomplete’ (one to three cycles) and ‘no FLOT’ (0 cycles). Progression‐free survival (PFS) and overall survival (OS) were compared. There is a statistically significant PFS advantage for the ‘FLOT complete’ group compared to ‘no FLOT’ ( p = .028) in the total patient cohort and a tendency for an OS benefit. In the subgroup of patients with lymph node metastasis in surgical specimen (ypN+ cohort, n = 91), the PFS advantage of ‘FLOT complete’ was diminished and statistically no longer significant, and there is no OS benefit for these patients. However, multivariate analysis confirmed a significant PFS benefit for ‘FLOT complete’ both in the total cohort ( p = .011) and in ypN+ patients ( p = .018). These findings suggest that full adjuvant FLOT is beneficial even for OGA patients with low tumour regression; however, its efficacy appears reduced in those with lymph node metastasis, warranting further investigation into individualising treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsEsophagogastric JunctionAdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsHumansMaleFemaleMiddle AgedNeoadjuvant TherapyChemotherapy, AdjuvantLeucovorinFluorouracilAgedOxaliplatinDocetaxelAdultRetrospective StudiesSurvival Rate

Stichwörter der Autor:innen

FLOTadjuvant chemotherapygastric adenocarcinomaoesophagogastric junction adenocarcinomatumour regression

Substanzen

LeucovorinFluorouracilOxaliplatinDocetaxel

Autor:innen und Institutionen

  • Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Gastrointestinal Cancer Group Cologne GCGC, University of Cologne, Cologne, Germany.
  • Department of General, Visceral, Cancer and Transplantation Surgery, University Hospital Cologne, Cologne, Germany.
  • Faculty of Medicine and University Hospital of Cologne, Institute of Pathology, University of Cologne, Cologne, Germany.

ORCID-Profile: Max Kraemer

Zitieren

APA

Kraemer, M., Wirsik, N. M., Alakus, H., Schloesser, H. A., Fuchs, H., Schroeder, W., Bruns, C. J., Lyu, S. I., Baehr, F., Zander, T., & Quaas, A. (2025). Adjuvant FLOT provides survival benefit for oesophagogastric junction and gastric adenocarcinoma patients with low tumour regression after neoadjuvant chemotherapy. International Journal of Cancer. https://doi.org/10.1002/ijc.70048

Vancouver

Kraemer M, Wirsik NM, Alakus H, Schloesser HA, Fuchs H, Schroeder W, et al. Adjuvant FLOT provides survival benefit for oesophagogastric junction and gastric adenocarcinoma patients with low tumour regression after neoadjuvant chemotherapy. International Journal of Cancer. 2025. doi:10.1002/ijc.70048

BibTeX
@article{Kraemer2025,
  author = {Kraemer, Max and Wirsik, Naita M and Alakus, Hakan and Schloesser, Hans A and Fuchs, Hans and Schroeder, Wolfgang and Bruns, Christiane J and Lyu, Su Ir and Baehr, Friederike and Zander, Thomas and Quaas, Alexander},
  title = {Adjuvant FLOT provides survival benefit for oesophagogastric junction and gastric adenocarcinoma patients with low tumour regression after neoadjuvant chemotherapy},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.70048}
}
Kostenlos starten →